Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)

摘要

Pemetrexed-related interstitial lung disease (ILD) reported from two post marketing surveillance were re-assessed by an advisory board. The results suggest that pemetrexed-related ILD risk is at similar level as other anti-cancer drugs under clinical settings.